"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

Poseida’s partnerships with Roche and Astellas aim to advance CAR-T therapies. See PSTX stock details and the impact of ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...

The man charged with attempting to assassinate Donald Trump after allegedly positioning himself with a rifle outside one of the former president’s Florida golf courses is due to appear in court ...

Uttar Pradesh CM Yogi Adityanath highlighted the BJP's achievements in Haryana during a public meeting in Bhiwani, focusing on improved connectivity and new institutions. He criticized Congress ...